CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade WUXI BIO - 2269 CFD

    12.85
    1.18%
    0.25
    Low: 12.65
    High: 13.05
    Market Trading Hours* (UTC) Opens on Wednesday at 01:30

    Mon - Fri: 01:30 - 04:00 05:00 - 08:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.25
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.021963 %
    Charges from full value of position ($-4.17)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.021963%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.000045 %
    Charges from full value of position ($0.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.000045%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency HKD
    Margin 5%
    Stock exchange Hong Kong
    Commission on trade 0%

    *Information provided by Capital.com

    WuXi Biologics (Cayman) Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

    More ESG coverage

    Key Stats
    Prev. Close* 12.7
    Open* 12.7
    1-Year Change* -74.65%
    Day's Range* 12.65 - 13.05
    52 wk Range 25.85-72.50
    Average Volume (10 days) 40.20M
    Average Volume (3 months) 659.20M
    Market Cap 120.71B
    P/E Ratio 27.37
    Shares Outstanding 4.26B
    Revenue 17.99B
    EPS 1.04
    Dividend (Yield %) N/A
    Beta 1.35
    Next Earnings Date Mar 22, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 23, 2024 12.80 0.00 0.00% 12.80 13.10 12.60
    Apr 22, 2024 12.70 0.15 1.20% 12.55 12.85 12.30
    Apr 19, 2024 12.55 -0.45 -3.46% 13.00 13.00 12.40
    Apr 18, 2024 13.20 -0.05 -0.38% 13.25 13.50 12.90
    Apr 17, 2024 13.20 0.20 1.54% 13.00 13.45 12.90
    Apr 16, 2024 12.90 -0.50 -3.73% 13.40 13.40 12.75
    Apr 15, 2024 13.50 -0.10 -0.74% 13.60 13.85 13.30
    Apr 12, 2024 13.75 0.00 0.00% 13.75 14.00 13.55
    Apr 11, 2024 13.95 0.00 0.00% 13.95 14.05 13.65
    Apr 10, 2024 14.20 -0.10 -0.70% 14.30 14.85 14.05
    Apr 9, 2024 14.25 0.25 1.79% 14.00 14.40 13.90
    Apr 8, 2024 14.00 0.80 6.06% 13.20 14.20 13.10
    Apr 5, 2024 13.25 -0.35 -2.57% 13.60 13.60 12.80
    Apr 3, 2024 13.95 -0.10 -0.71% 14.05 14.40 13.80
    Apr 2, 2024 14.05 -0.50 -3.44% 14.55 14.60 13.95
    Mar 28, 2024 14.20 0.45 3.27% 13.75 14.85 13.70
    Mar 27, 2024 13.65 0.15 1.11% 13.50 14.20 12.90
    Mar 26, 2024 13.40 -0.55 -3.94% 13.95 14.05 13.40
    Mar 25, 2024 13.90 0.25 1.83% 13.65 14.15 13.40
    Mar 22, 2024 12.90 -1.00 -7.19% 13.90 13.90 12.80

    WUXI BIO Events

    Time (UTC) Country Event
    Wednesday, June 19, 2024

    Time (UTC)

    10:59

    Country

    HK

    Event

    WuXi Biologics (Cayman) Inc Annual Shareholders Meeting
    WuXi Biologics (Cayman) Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Wednesday, June 26, 2024

    Time (UTC)

    02:00

    Country

    HK

    Event

    WuXi Biologics (Cayman) Inc Annual Shareholders Meeting
    WuXi Biologics (Cayman) Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Friday, August 23, 2024

    Time (UTC)

    10:59

    Country

    HK

    Event

    Half Year 2024 WuXi Biologics (Cayman) Inc Earnings Release
    Half Year 2024 WuXi Biologics (Cayman) Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 15268.7 10290 5612.38 3983.69 2534.45
    Revenue 15268.7 10290 5612.38 3983.69 2534.45
    Cost of Revenue, Total 8544.65 5461.15 3079.42 2324.86 1516.7
    Gross Profit 6724.01 4828.9 2532.97 1658.83 1017.76
    Total Operating Expense 9846.51 6257.74 3606.52 2834.33 1796.73
    Selling/General/Admin. Expenses, Total 1691.03 1157.25 726.913 451.21 270.151
    Research & Development 682.818 501.583 303.734 259.651 169.287
    Interest Expense (Income) - Net Operating -837.823 -662.622 -361.003 -87.347 -96.846
    Unusual Expense (Income) 55.94
    Other Operating Expenses, Total -234.164 -199.62 -142.538 -114.042 -118.499
    Operating Income 5422.15 4032.31 2005.86 1149.36 737.722
    Interest Income (Expense), Net Non-Operating -64.382 -39.191 -40.1 -22.724 0
    Net Income Before Taxes 5357.77 3993.12 1965.76 1126.63 737.722
    Net Income After Taxes 4549.91 3508.58 1692.69 1010.34 630.465
    Net Income Before Extra. Items 4420.29 3388.48 1688.89 1013.8 630.592
    Net Income 4420.29 3388.48 1688.89 1013.8 630.592
    Income Available to Common Excl. Extra. Items 4420.29 3388.48 1688.89 1013.8 630.592
    Income Available to Common Incl. Extra. Items 4420.29 3388.48 1688.89 1013.8 630.592
    Diluted Net Income 4420.29 3388.48 1688.89 1013.8 630.592
    Diluted Weighted Average Shares 4375.91 4421.8 4209.17 3997.17 3941.65
    Diluted EPS Excluding Extraordinary Items 1.01014 0.76631 0.40124 0.25363 0.15998
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS 1.01388 0.76645 0.40168 0.25395 0.17237
    Minority Interest -129.62 -120.103 -3.808 3.468 0.127
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total revenue 8492.05 8062.22 7206.44 5883.3 4406.75
    Revenue 8492.05 8062.22 7206.44 5883.3 4406.75
    Cost of Revenue, Total 4931.41 4751.41 3793.23 3351.23 2109.92
    Gross Profit 3560.63 3310.81 3413.21 2532.06 2296.83
    Total Operating Expense 5884.25 5592.86 4253.64 3930.09 2327.65
    Selling/General/Admin. Expenses, Total 916.83 1032.98 658.053 616.084 541.162
    Research & Development 341.44 411.69 271.128 386.208 115.375
    Interest Expense (Income) - Net Operating -126.938 -518.888 -318.935 -360.983 -301.639
    Unusual Expense (Income) 7.374
    Other Operating Expenses, Total -185.867 -84.329 -149.835 -62.453 -137.167
    Operating Income 2607.79 2469.36 2952.8 1953.21 2079.1
    Interest Income (Expense), Net Non-Operating -78.819 -41.721 -22.661 -18.317 -20.874
    Net Income Before Taxes 2528.98 2427.64 2930.14 1934.89 2058.23
    Net Income After Taxes 2337.86 1928.68 2621.23 1625.8 1882.78
    Minority Interest -71.185 -43.459 -86.161 -79.465 -40.638
    Net Income Before Extra. Items 2266.68 1885.22 2535.06 1546.34 1842.14
    Net Income 2266.68 1885.22 2535.06 1546.34 1842.14
    Income Available to Common Excl. Extra. Items 2266.68 1885.22 2535.06 1546.34 1842.14
    Income Available to Common Incl. Extra. Items 2266.68 1885.22 2535.06 1546.34 1842.14
    Diluted Net Income 2266.68 1885.22 2535.06 1546.34 1842.14
    Diluted Weighted Average Shares 4349.85 4365.48 4386.34 4435.76 4407.83
    Diluted EPS Excluding Extraordinary Items 0.52109 0.43185 0.57795 0.34861 0.41792
    Diluted Normalized EPS 0.52318 0.43513 0.5782 0.34862 0.41805
    Dividends per Share - Common Stock Primary Issue 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 18469.9 19529.7 14204.4 9671.86 5745.19
    Cash and Short Term Investments 8714.32 11126.5 8480.56 6748.5 4084.4
    Cash & Equivalents
    Total Receivables, Net 6126.26 4850.95 3121.52 1772.55 1100.9
    Accounts Receivable - Trade, Net 5144.23 3256.3 2356.77 1374.62 798.884
    Total Inventory 2280.91 1687.38 1084.19 399.389 227.189
    Prepaid Expenses 25.281 161.917 156.184 4.096 3.153
    Other Current Assets, Total 1323.1 1703.02 1361.91 747.321 329.55
    Total Assets 49564.4 44032.6 28963.6 17602.3 9393.15
    Property/Plant/Equipment, Total - Net 25916 19755.8 12870.3 6796.39 2903.9
    Property/Plant/Equipment, Total - Gross 28404.4 21452 14052.9 7625.59 3460.67
    Accumulated Depreciation, Total -2488.38 -1696.21 -1182.56 -829.199 -556.774
    Other Long Term Assets, Total 281.445 289.211 150.484 80.611 219.972
    Total Current Liabilities 9318.6 8255.69 4498.25 2871.2 1318.76
    Accounts Payable 794.388 617.784 646.002 185.81 220.983
    Accrued Expenses 912.852 781.009 500.993 257.043 142.161
    Notes Payable/Short Term Debt 0 2121.9 767.126 506.107 0
    Current Port. of LT Debt/Capital Leases 1470.49 103.561 60.711 26.489
    Other Current Liabilities, Total 6140.87 4631.44 2523.42 1895.75 955.613
    Total Liabilities 14517 11754 8399.17 4817.91 1399.4
    Total Long Term Debt 2951.17 2069.83 2504.14 1661.35 0
    Long Term Debt 1461.56 640.513 1837.62 1395.24
    Capital Lease Obligations 1489.61 1429.32 666.513 266.112
    Deferred Income Tax 132.076 124.211 180.885 24.734 2.68
    Other Liabilities, Total 949.462 876.726 880.948 148.885 77.485
    Total Equity 35047.4 32278.6 20564.4 12784.4 7993.75
    Common Stock 0.233 0.235 0.225 0.214 0.202
    Retained Earnings (Accumulated Deficit) 13584.9 8232.81 4405.27 2511.35 1331.54
    Total Liabilities & Shareholders’ Equity 49564.4 44032.6 28963.6 17602.3 9393.15
    Total Common Shares Outstanding 4225.26 4259 4084.76 3883.62 3677.86
    Cash 6395.22 9003.28 7095.73 6205.5 4084.4
    Short Term Investments 2319.1 2123.2 1384.82 543 0
    Long Term Investments 2709.21 2202.82 1073.5 452.162 192.277
    Additional Paid-In Capital 22102 27044.5 15949.7 10260.2 6650.21
    Intangibles, Net 548.778 600.654 391.857 415.845 331.813
    Minority Interest 1165.67 427.573 334.951 111.737 0.473
    Other Equity, Total -547.494 -449.329 211.976 12.594 11.803
    Goodwill, Net 1529.91 1529.91 185.408 185.408
    Note Receivable - Long Term 109.171 124.485 87.672
    Unrealized Gain (Loss) -92.236 -32.505 -2.686
    Treasury Stock - Common 0 -2517.11
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total Current Assets 17877.5 18469.9 20657.1 19529.7 21979.3
    Cash and Short Term Investments 8694.26 8714.32 9864.3 11126.5 13939.3
    Cash & Equivalents
    Short Term Investments 1339.13 2319.1 1729.01 2123.2 2657.62
    Total Receivables, Net 5992.79 6126.26 6838.07 4850.95 4678.4
    Accounts Receivable - Trade, Net 5376.21 5144.23 5547.89 3256.3 2902.09
    Total Inventory 1965.13 2280.91 2143.76 1687.38 1706.76
    Prepaid Expenses 50.693 25.281 30.119 161.917 161.644
    Other Current Assets, Total 1174.65 1323.1 1780.81 1703.02 1493.19
    Total Assets 52141.2 49564.4 47473.3 44032.6 43580.8
    Property/Plant/Equipment, Total - Net 28994.9 25916 21845.9 19755.8 17738.7
    Goodwill, Net 1529.91 1529.91 1529.91 1529.91 1334.14
    Intangibles, Net 543.961 548.778 563.981 600.654 585.498
    Long Term Investments 2760.16 2709.21 2430.55 2202.82 1608.7
    Other Long Term Assets, Total 333.374 281.445 328.952 289.211 249.942
    Total Current Liabilities 8140.85 9318.6 8996.15 8255.69 5441.56
    Accounts Payable 573.196 794.388 995.329 617.784 534.613
    Accrued Expenses 413.759 912.852 402.033 781.009 407.15
    Notes Payable/Short Term Debt 0 0 2347.16 2121.9 1160.64
    Current Port. of LT Debt/Capital Leases 1280.53 1470.49 126.249 103.561 133.438
    Other Current Liabilities, Total 5873.37 6140.87 5125.38 4631.44 3205.72
    Total Liabilities 14402.9 14517 13011.6 11754 10360
    Total Long Term Debt 3860.48 2951.17 1925.15 2069.83 3305.35
    Long Term Debt 1659.37 1461.56 531.898 640.513 2073.93
    Capital Lease Obligations 2201.11 1489.61 1393.25 1429.32 1231.42
    Deferred Income Tax 126.609 132.076 162.313 124.211 197.675
    Minority Interest 1305.94 1165.67 1018.94 427.573 363.044
    Other Liabilities, Total 968.975 949.462 909.006 876.726 1052.39
    Total Equity 37738.4 35047.4 34461.7 32278.6 33220.7
    Common Stock 0.234 0.233 0.235 0.235 0.234
    Additional Paid-In Capital 22571 22102 24056.1 27044.5 26975.8
    Retained Earnings (Accumulated Deficit) 16156.5 13584.9 11162.1 8232.81 6374.18
    Other Equity, Total -876.51 -547.494 -674.65 -449.329 -126.799
    Total Liabilities & Shareholders’ Equity 52141.2 49564.4 47473.3 44032.6 43580.8
    Total Common Shares Outstanding 4248.53 4225.26 4263.53 4259 4238.12
    Payable/Accrued
    Cash 7355.13 6395.22 8135.29 9003.28 11281.7
    Note Receivable - Long Term 101.399 109.171 116.935 124.485 84.464
    Unrealized Gain (Loss) -112.851 -92.236 -82.057 -32.505 -2.686
    Treasury Stock - Common 0 0 0 -2517.11
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 5357.77 3993.12 1965.76 1126.63 737.722
    Cash From Operating Activities 5541.67 3431.26 1881.28 1208.08 761.607
    Cash From Operating Activities 743.608 434.114 270.96 200.551 131.563
    Non-Cash Items 943.362 269.668 73.808 154.147 180.193
    Cash Taxes Paid 585.662 349.986 94.238 78.001 52.103
    Cash Interest Paid 108.239 83.2 82.544 49.801 0
    Changes in Working Capital -1560.13 -1313.31 -461.301 -294.066 -297.84
    Cash From Investing Activities -5908.25 -9601.67 -7216.28 -4493.93 -416.074
    Capital Expenditures -5868.39 -6523.11 -6024.78 -3234.66 -1673.84
    Other Investing Cash Flow Items, Total -39.862 -3078.56 -1191.5 -1259.28 1257.77
    Cash From Financing Activities -2591.59 8209.46 6565.64 5412.82 3206.82
    Financing Cash Flow Items 507.88 -104.338 159.514 -8.442 0.898
    Issuance (Retirement) of Debt, Net -295.018 -146.826 821.38 1887.65 0
    Foreign Exchange Effects 350.113 -131.502 -340.398 -5.871 28.157
    Net Change in Cash -2608.06 1907.55 890.239 2121.1 3580.51
    Amortization 57.066 47.669 32.049 20.814 9.969
    Issuance (Retirement) of Stock, Net -2804.45 8460.62 5584.75 3533.61 3205.93
    Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
    Cash From Operating Activities 5541.67 1457.92 3431.26 798.005 1881.28
    Cash Interest Paid 108.239 43.912 83.2 41.598 82.544
    Changes in Working Capital 5541.67 1457.92 3431.26 798.005 1881.28
    Cash From Investing Activities -5908.25 -2362.79 -9601.67 -7741.4 -7216.28
    Capital Expenditures -5868.39 -2684.5 -6523.11 -4073.13 -6024.78
    Other Investing Cash Flow Items, Total -39.862 321.713 -3078.56 -3668.27 -1191.5
    Cash From Financing Activities -2591.59 -218.943 8209.46 11215.5 6565.64
    Financing Cash Flow Items 507.88 483.686 -104.338 -89.034 159.514
    Issuance (Retirement) of Stock, Net -2804.45 -691.056 8460.62 10977.7 5584.75
    Issuance (Retirement) of Debt, Net -295.018 -11.573 -146.826 326.831 821.38
    Foreign Exchange Effects 350.113 255.822 -131.502 -86.161 -340.398
    Net Change in Cash -2608.06 -867.99 1907.55 4185.98 890.239

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    WuXi Biologics Company profile

    About WuXi Biologics (Cayman) Inc

    WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing of biologics services. The Company's technology platforms include WuXiBody TM bispecific antibody technology platform and antibody drug conjugates (ADC) technology platform. It has brought in several new projects into its pipeline. The Company has a vaccine manufacturing facility and produces vaccines for customers to supply the global market. The Company conducts its businesses within the China market and to overseas markets, such as North America, Europe and other markets.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, WuXi Biologics (Cayman) Inc revenues increased 83% to RMB10.29B. Net income increased from RMB1.69B to RMB3.39B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from FV gain - unlisted investments at FVTPL increase from RMB3M to RMB74.4M (income).

    Industry: Biopharmaceuticals

    馬山梅梁路108號
    WUXI
    JIANGSU
    CN

    Income Statement

    • Annual
    • Quarterly

    News

    We’re partnering with Newsquawk

    Filter out the noise and focus on the news that matters.

    08:32, 23 April 2024

    US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft

    The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.

    15:56, 22 April 2024

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    People also watch

    US100

    17,521.70 Price
    +1.830% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    XRP/USD

    0.56 Price
    -1.940% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    BTC/USD

    66,380.10 Price
    -0.350% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    ETH/USD

    3,211.90 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading